INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
Trial details
- Registry ID
- NCT07224321
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 DiabetesNCT07224321 | Mannkind Corporation | Phase 2 | Recruiting | 2027-03Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |